OverviewSuggest Edit

3DBiopsy is a company developing a system for diagnosis and treatment planning of prostate cancer. It provides the image-guided software designed to create a transperineal biopsy plan, the integrated pathology system (IPS) to receive unfragmented specimens, and the TRUS biopsy device to receive a tissue sample.

Latest Updates

Employees (est.) (Oct 2021)3
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at 3DBiopsy

Brad J. Buscher

Brad J. Buscher

Business Development Officer
Todd Anderson

Todd Anderson

Chief Financial Officer
E. David Crawford

E. David Crawford

Chief Scientific Officer and Founder
Marshall Lucia

Marshall Lucia

Co-Founder, leads the development of the 3D pathology software
Show more

3DBiopsy Financials and Metrics

Summary Metrics

Founding Date


3DBiopsy total Funding

$2.2 m

3DBiopsy latest funding size

$850 k

Time since last funding

3 years ago
3DBiopsy's latest funding round in August 2018 was reported to be $850 k. In total, 3DBiopsy has raised $2.2 m
Show all financial metrics

3DBiopsy Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

3DBiopsy Online and Social Media Presence

Embed Graph

3DBiopsy Frequently Asked Questions

  • When was 3DBiopsy founded?

    3DBiopsy was founded in 2012.

  • Who are 3DBiopsy key executives?

    3DBiopsy's key executives are Brad J. Buscher, Todd Anderson and E. David Crawford.

  • How many employees does 3DBiopsy have?

    3DBiopsy has 3 employees.

  • Who are 3DBiopsy competitors?

    Competitors of 3DBiopsy include Ambu USA, Trice Medical and Infraredx.